TY - JOUR
T1 - Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies
T2 - Spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention
AU - Safdar, A.
AU - Rodriguez, G. H.
AU - Mihu, C. N.
AU - Mora-Ramos, L.
AU - Mulanovich, V.
AU - Chemaly, R. F.
AU - Champlin, R. E.
AU - Khouri, I.
N1 - Funding Information:
Supported in part by Cancer Center Support grant CA16672 from the National Institutes of Health. A portion of this study was presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology and Infectious Diseases Society, Washington, DC, 25–28 October 2008.
PY - 2010/2
Y1 - 2010/2
N2 - The overall risk of infections is lower in patients undergoing non-myeloablative allogeneic stem cell transplantation (NST) than in conventional stem cell transplant recipients. We sought to evaluate conditions associated with increased risk of infections after NST. In 81 patients, 187 infection episodes were noted; chronic lymphocytic leukemia (138 episodes/100 person-years) and recipients of matched unrelated donor graft (128 episodes/100 person-years) had higher risk of infection. Only half of the cytomegalovirus (CMV) infections occurred 31-100 days after transplantation. Most patients with CMV infection were non-neutropenic (100%), had lymphoma (76%), were younger (<55 years; 72%) and had received matched related donor (MRD) graft (72%). However, graft-versus-host disease (GVHD) was present in only 15% of these patients. Seven (78%) of nine invasive fungal infections (IFI) were diagnosed >100 days after NST and were associated with high mortality (78%). Most patients with IFI were also not neutropenic (100%), had received MRD graft (100%), had lymphoma (78%) and were given systemic steroids (78%); unlike CMV infection, 67% of these patients also had GVHD. On the basis of our results, we propose that NST recipients with lymphoma treated with high-dose corticosteroids for GVHD be considered for antifungal prophylaxis or pre-emptive antifungal therapy.
AB - The overall risk of infections is lower in patients undergoing non-myeloablative allogeneic stem cell transplantation (NST) than in conventional stem cell transplant recipients. We sought to evaluate conditions associated with increased risk of infections after NST. In 81 patients, 187 infection episodes were noted; chronic lymphocytic leukemia (138 episodes/100 person-years) and recipients of matched unrelated donor graft (128 episodes/100 person-years) had higher risk of infection. Only half of the cytomegalovirus (CMV) infections occurred 31-100 days after transplantation. Most patients with CMV infection were non-neutropenic (100%), had lymphoma (76%), were younger (<55 years; 72%) and had received matched related donor (MRD) graft (72%). However, graft-versus-host disease (GVHD) was present in only 15% of these patients. Seven (78%) of nine invasive fungal infections (IFI) were diagnosed >100 days after NST and were associated with high mortality (78%). Most patients with IFI were also not neutropenic (100%), had received MRD graft (100%), had lymphoma (78%) and were given systemic steroids (78%); unlike CMV infection, 67% of these patients also had GVHD. On the basis of our results, we propose that NST recipients with lymphoma treated with high-dose corticosteroids for GVHD be considered for antifungal prophylaxis or pre-emptive antifungal therapy.
KW - Antimicrobial prophylaxis
KW - Guidelines
KW - Infections
KW - Non-myeloablative stem cell transplantation
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=76749144119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749144119&partnerID=8YFLogxK
U2 - 10.1038/bmt.2009.149
DO - 10.1038/bmt.2009.149
M3 - Article
C2 - 19561648
AN - SCOPUS:76749144119
SN - 0268-3369
VL - 45
SP - 339
EP - 347
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 2
ER -